Recursion Pharmaceuticals (NasdaqGS:RXRX) recently announced a $500 million Follow-on Equity Offering and revealed mixed earnings results for Q4 2024, which showed declining quarterly sales and ...
Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future ...
Q4 2024 Earnings Call Transcript February 28, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported ...
Hosted on MSN19h
Company News for Mar 3, 2025The AES Corp.’s (AES) shares jumped 11.7% after the company reported fourth-quarter 2024 adjusted earnings per share of $0.54, surpassing the Zacks Consensus Estimate of $0.34. Shares of Recursion ...
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price dropped by Leerink Partners from $7.00 to ...
EST Cathie Wood’s ARK Investment buys 653K shares of Recursion Pharmaceuticals (RXRX) todayDiscover the Best Stocks and Maximize Your ...
TD Cowen analyst Brendan Smith maintained a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report) today. The company’s shares ...
The clinical-stage TechBio company posted a loss of $0.53 per share for Q4, wider than the $0.41 loss analysts had forecast. Revenue came in at $4.55 million, significantly below the consensus ...
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Friday reported a loss of $178.9 million in its fourth quarter. On a per-share basis, the Salt Lake City-based ...
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological ...
ARK Invest purchased $9.3 million worth of Coinbase shares during a crypto market downturn while simultaneously selling $8.6 ...
Roche's drug portfolio shows promise, but mixed indicators reveal uncertainties. Check out the risks, opportunities, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback